Treat & extend in neovascular age-related macular degeneration: how we got here and where do we go next?
作者信息
Chaudhary Varun
机构信息
Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Department of Surgery, McMaster University, Hamilton, ON, Canada.
出版信息
Eye (Lond). 2023 Mar;37(4):581-583. doi: 10.1038/s41433-022-02221-0. Epub 2022 Sep 5.
Abstract
摘要
相似文献
1
Treat & extend in neovascular age-related macular degeneration: how we got here and where do we go next?新生血管性年龄相关性黄斑变性的治疗与拓展：我们如何走到这一步以及下一步何去何从？
Eye (Lond). 2023 Mar;37(4):581-583. doi: 10.1038/s41433-022-02221-0. Epub 2022 Sep 5.
2
MACUSTAR-Do We Have Accurate and Precise Visual Function Outcome Measures Needed to Conduct a Multicenter Clinical Trial of an Early Treatment for Non-Neovascular Age-Related Macular Degeneration?MACUSTAR研究——我们是否拥有开展非新生血管性年龄相关性黄斑变性早期治疗多中心临床试验所需的准确且精确的视觉功能结局测量指标？
JAMA Ophthalmol. 2022 Aug 1;140(8):789-790. doi: 10.1001/jamaophthalmol.2022.2134.
3
Impact of COVID-19 restrictions on the treatment of neovascular age-related macular degeneration.2019冠状病毒病限制措施对新生血管性年龄相关性黄斑变性治疗的影响
Acta Ophthalmol. 2024 May;102(3):e404-e405. doi: 10.1111/aos.15766. Epub 2023 Sep 19.
4
Mental Status and Feasibility of an Intravitreal Ranibizumab Treat-and-Extend Regimen in Patients with Neovascular Age-Related Macular Degeneration.玻璃体内雷珠单抗按需治疗与延长治疗方案治疗新生血管性年龄相关性黄斑变性患者的精神状态和可行性。
Adv Ther. 2022 Mar;39(3):1403-1416. doi: 10.1007/s12325-022-02052-1. Epub 2022 Feb 3.
5
Increasing concentrations of intravitreal therapies for neovascular age-related macular degeneration.用于治疗新生血管性年龄相关性黄斑变性的玻璃体内注射疗法浓度不断增加。
Lancet. 2024 Mar 23;403(10432):1110-1111. doi: 10.1016/S0140-6736(24)00229-0. Epub 2024 Mar 7.
6
Ranibizumab Injection (Susvimo) Implant Septum Dislodgement in a Patient With Neovascular Age-Related Macular Degeneration.雷珠单抗注射液（Susvimo）植入物隔膜移位在一名新生血管性年龄相关性黄斑变性患者中的病例报告
JAMA Ophthalmol. 2022 Aug 1;140(8):832. doi: 10.1001/jamaophthalmol.2022.2495.
7
Macular atrophy development in neovascular age-related macular degeneration.新生血管性年龄相关性黄斑变性中的黄斑萎缩发展
Eur J Ophthalmol. 2022 Jan;32(1):NP307-NP308. doi: 10.1177/1120672120948730. Epub 2020 Aug 5.
8
Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study).雷珠单抗生物类似药（拉珠单抗）与创新型雷珠单抗（雷珠单抗注射液）治疗新生血管性年龄相关性黄斑变性（n-AMD）的疗效和安全性比较（BIRA研究）
Eye (Lond). 2022 May;36(5):1106-1107. doi: 10.1038/s41433-021-01616-9. Epub 2021 Jun 22.
9
The promise of long-term treatment for neovascular age-related macular degeneration.新生血管性年龄相关性黄斑变性的长期治疗前景。
Lancet. 2024 Apr 20;403(10436):1517-1519. doi: 10.1016/S0140-6736(24)00428-8. Epub 2024 Mar 27.
10
Real-world evidence for neovascular age-related macular degeneration: a practical approach.新生血管性年龄相关性黄斑变性的真实世界证据：一种实用方法。
Eye (Lond). 2023 Jan;37(1):1-3. doi: 10.1038/s41433-022-02151-x. Epub 2022 Jul 8.
引用本文的文献
1
To Treat or Not to Treat? Resolving the Question of Subretinal and Intraretinal Fluid in Age-Related Macular Degeneration: A Narrative Review.治疗还是不治疗？解决年龄相关性黄斑变性中视网膜下液和视网膜内液的问题：一项叙述性综述。
Ophthalmol Ther. 2025 Mar;14(3):489-514. doi: 10.1007/s40123-025-01093-3. Epub 2025 Feb 4.
本文引用的文献
1
A Randomized, Controlled Trial of Treat-and-Extend vs. Pro Re Nata Regimen for Neovascular Age-Related Macular Degeneration.治疗并延长方案与按需治疗方案用于新生血管性年龄相关性黄斑变性的随机对照试验
Front Med (Lausanne). 2022 Jun 20;9:852519. doi: 10.3389/fmed.2022.852519. eCollection 2022.
2
Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis.治疗和延长与替代抗血管内皮生长因子方案治疗 nAMD 的疗效、安全性和治疗负担：系统评价和荟萃分析。
Eye (Lond). 2023 Jan;37(1):6-16. doi: 10.1038/s41433-022-02020-7. Epub 2022 Apr 8.
3
OCT Predictors of 3-Year Visual Outcome for Type 3 Macular Neovascularization.OCT 预测 3 年 III 型黄斑新生血管的视力结局。
Ophthalmol Retina. 2022 Jul;6(7):586-594. doi: 10.1016/j.oret.2022.02.010. Epub 2022 Feb 25.
4
Complement cascade inhibition in geographic atrophy: a review.补体级联抑制在地图样萎缩中的研究进展。
Eye (Lond). 2022 Feb;36(2):294-302. doi: 10.1038/s41433-021-01765-x. Epub 2022 Jan 9.
5
IMPACT OF FLUID COMPARTMENTS ON FUNCTIONAL OUTCOMES FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Literature Review.液体腔室对新生血管性年龄相关性黄斑变性患者功能结局的影响：一项系统文献综述
Retina. 2022 Apr 1;42(4):589-606. doi: 10.1097/IAE.0000000000003283.
6
Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study.抗血管内皮生长因子药物玻璃体腔内注射治疗新生血管性年龄相关性黄斑变性的长期疗效：一项真实世界研究。
BMC Ophthalmol. 2021 Aug 14;21(1):300. doi: 10.1186/s12886-021-02055-6.
7
EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial.玻璃体内注射阿柏西普治疗新生血管性年龄相关性黄斑变性的疗效和安全性：ARIES 研究：一项随机临床试验。
Retina. 2021 Sep 1;41(9):1911-1920. doi: 10.1097/IAE.0000000000003128.
8
Insights From Survival Analyses During 12 Years of Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration.抗血管内皮生长因子治疗新生血管性年龄相关性黄斑变性 12 年的生存分析结果。
JAMA Ophthalmol. 2021 Jan 1;139(1):57-67. doi: 10.1001/jamaophthalmol.2020.5044.
9
C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.C5 抑制剂阿伐西普 Pegol 治疗年龄相关性黄斑变性相关地图状萎缩：一项随机关键性 2/3 期试验。
Ophthalmology. 2021 Apr;128(4):576-586. doi: 10.1016/j.ophtha.2020.08.027. Epub 2020 Sep 1.
10
The long-term effects of anti-vascular endothelial growth factor therapy on the optical coherence tomography angiographic appearance of neovascularization in age-related macular degeneration.抗血管内皮生长因子疗法对年龄相关性黄斑变性新生血管形成的光学相干断层扫描血管造影表现的长期影响。
Int J Retina Vitreous. 2020 Aug 20;6:39. doi: 10.1186/s40942-020-00242-z. eCollection 2020.
Zotero 插件